AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21472620
Drug: Standardised rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised rehabilitation therapy with pelvic floor re-education (control group)
Trial: 17881186
Drug: Aspirin 100mg
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 100mg plus long-acting propranolol 80mg
Trial: 17881186
Drug: Aspirin 100mg
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 100mg plus placebo
Trial: 7706598
Drug: Restricted intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restricted intake of thiamin, riboflavin, and vitamin B6 (daily diet providing no more than 55% of the Dutch RDA for these vitamins)
Trial: 7706598
Drug: Regular intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular intake of vitamins (supplemented at twice the RDA level)
Trial: 24090588
Drug: Simvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (10 mg per day in month 1, 20 mg per day in month 2, and 20-40 mg per day in months 3-12)
Trial: 19035858
Drug: Degarelix 240/160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Degarelix 240/160 mg
Trial: 8799526
Drug: Artemisinin monotherapy
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin monotherapy (500 mg single dose followed by another 500 mg on day 1 and then 250 mg twice daily for 4 days)
Trial: 8799526
Drug: Artemisinin in
RxNorm normalized name: Product containing artemisinin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin in combination with mefloquine (500 mg single dose followed by 750 mg on day 1 and then 250 mg three times daily for one more day; Mefloquine 250 mg three times daily for the first day)
Trial: 8799526
Drug: Artemisinin monotherapy
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin monotherapy
Trial: 8799526
Drug: Artemisinin in
RxNorm normalized name: Product containing artemisinin in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin in combination with mefloquine
Trial: 1633906
Drug: Glucocorticoids (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoids (group A) - intravenous hydrocortisone, 100 mg immediately after ultrasound-directed oocyte recovery, followed by prednisolone, 10 mg three times per day for 5 days, then 10 mg two times a day for 3 days, and 10 mg/d for 2 days.
Trial: 1633906
Drug: No glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No glucocorticoid treatment (group B).
Trial: 1633906
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received luteal support with intramuscular injections of gestone 100 mg/d.
Trial: 1633906
Drug: No glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No glucocorticoid treatment (group B)
Trial: 6640552
Drug: Human lymphoblastoid
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human lymphoblastoid interferon at a dose of 3.0 X 10(6) units/m2 three times/week for 6 weeks, followed by maintenance treatment with interferon (3.0 X 10(6) units/m2 once/week) for those who did not progress.
Trial: 6640552
Drug: Placebo maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo maintenance (no further treatment) for patients who did not progress after initial treatment.
Trial: 21443602
Drug: Alitretinoin 30
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alitretinoin 30 mg once daily for 12 or 24 weeks
Trial: 21443602
Drug: Alitretinoin 10
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alitretinoin 10 mg once daily for 12 or 24 weeks
Trial: 19840748
Drug: 1g daily
RxNorm normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1g daily vitamin C treatment (Group II)
Trial: 19840748
Drug: No vitamin
RxNorm normalized name: Vitamin B12 NOS
DrugBank: Cyanocobalamin (DB00115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No vitamin C treatment (Group I)
Trial: 16490844
Drug: Anti-CTLA-4 monoclonal
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anti-CTLA-4 monoclonal antibody (up to 9 mg/kg every 3 weeks)
Trial: 10927048
Drug: Triptorelin (3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptorelin (3.75 mg)
Trial: 10927048
Drug: Leuprorelin acetate
RxNorm normalized name: Leuprorelin acetate
DrugBank: Leuprolide (DB00007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Leuprorelin acetate (3.75 mg)
Trial: 4646510
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (emphasizing good prognosis, early mobilization, physiotherapy)
Trial: 4646510
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (physiotherapy)
Trial: 28974406
Drug: CCH 0.58
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCH 0.58 mg plus vacuum therapy alone
Trial: 28974406
Drug: CCH 0.58
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CCH 0.58 mg plus vacuum therapy with penile modeling
Trial: 19833276
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L (0.1 mL/kg of preservative‐free 1% lidocaine pretreatment, slow rocuronium injection)
Trial: 19833276
Drug: Group R
RxNorm normalized name: Typhus group rickettsia Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group R (0.1 mL/kg of 0.9% NaCl pretreatment, rapid rocuronium injection)
Trial: 19833276
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (0.1 mL/kg of 0.9% NaCl pretreatment, slow rocuronium injection)
Trial: 19833276
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L vs Group R
Trial: 9252801
Drug: Tolcapone with
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolcapone with standard-release levodopa/benserazide formulations (50/12.5 mg, 100/25 mg, 200/50 mg)
Trial: 9252801
Drug: Tolcapone with
RxNorm normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolcapone with controlled-release levodopa/benserazide formulation (100/25 mg)
Trial: 8060907
Drug: Empathy-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empathy-treatment
Trial: 8060907
Drug: Facts-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facts-treatment
Trial: 20029208
Drug: Daily placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily placebo with pantoprazole rescue (n = 141)
Trial: 20029208
Drug: Daily pantoprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pantoprazole with placebo rescue (n = 62)
Trial: 3920861
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Sorbinil
Trial: 20589494
Drug: Tramadol 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 800 mg/day
Trial: 20589494
Drug: Hydromorphone (1.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromorphone (1.5, 3.0, and 6.0 mg)
Trial: 15699233
Drug: Men not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men not choline depleted (550 mg choline/d)
Trial: 10690245
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg) + Ivermectin (200 micrograms/kg)
Trial: 10690245
Drug: Albendazole (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (400 mg) + DEC (6 mg/kg)
Trial: 8699911
Drug: Topical pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical pilocarpine (candy-like pastille) administered in increasing dosages for 5 weeks
Trial: 8699911
Drug: Topical pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical pilocarpine (candy-like pastille)
Trial: 8699911
Drug: Topical pilocarpine
RxNorm normalized name: Pilocarpine
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical pilocarpine administration
Trial: 1873372
Drug: 100 mcg
RxNorm normalized name: Levo-T 100 MCG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mcg selenium daily for 5 weeks
Trial: 31815649
Drug: Upadacitinib (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upadacitinib (both doses)
Trial: 29182407
Drug: Metformin (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (conventional anti-diabetic doses)
Trial: 29182407
Drug: Control (non-treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (non-treatment mixed)
Trial: 24799181
Drug: HAL photodynamic
RxNorm normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HAL photodynamic therapy (PDT) with vaginal suppository, 5 hours before illumination with 50 J/cm² red coherent light (633 nm)
Trial: 24799181
Drug: HAL photodynamic
RxNorm normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HAL photodynamic therapy (PDT)
Trial: 15876944
Drug: Azithromycin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (10 mg/kg/d for 3 days weekly, for 3 weeks) with symptom-specific agents
Trial: 15876944
Drug: Symptom-specific agents
RxNorm normalized name: Pamprin Multi-Symptom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptom-specific agents alone
Trial: 9498512
Drug: 600 IU/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 IU/kg intravenous EPO three times weekly
Trial: 1978371
Drug: Ipsapirone 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipsapirone 15 mg
Trial: 1978371
Drug: Ipsapirone 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipsapirone 30 mg
Trial: 29178943
Drug: High-volume hemofiltration
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume hemofiltration (HVHF) at a dose of 70 ml/kg/hour for 48 hours
Trial: 19134020
Drug: Probiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplementation (Bifidobacterium longum (BL999) 1 x 10(7) CFU/g and Lactobacillus rhamnosus (LPR) 2 x 10(7) CFU/g)
Trial: 11642024
Drug: Vancomycin (23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (23 F per gram) in continuous infusion through a central venous catheter
Trial: 11642024
Drug: Teicoplanin (311‐357
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teicoplanin (311‐357 F a 400 mg vial) intramuscularly
Trial: 3058475
Drug: Propofol 1‐1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 1‐1.5 mg kg‐1 body weight
Trial: 3058475
Drug: Methohexitone 0.75‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methohexitone 0.75‐1 mg kg‐1 body weight
Trial: 24253484
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (MPA) 60 mg daily
Trial: 23860961
Drug: Alprostadil (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprostadil (0.4 μg/kg/day) in 100 ml sterile saline
Trial: 16623075
Drug: Irbesartan/HCTZ treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan/HCTZ treatment
Trial: 11336155
Drug: Jejunal meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jejunal meal feeding (liquid meal at 2 kcal/2 ml/min)
Trial: 8204290
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil 500 mg b.d. for 8 days (25 patients)
Trial: 8204290
Drug: Amoxycillin/clavulanate 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin/clavulanate 500 mg t.d.s for 8 days (22 patients)
Trial: 21427078
Drug: C24T variant
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C24T variant allele in MRP2 under macrolides treatment (Tacrolimus and Sirolimus)
Trial: 21427078
Drug: C24T variant
RxNorm normalized name: Valiant Barrier
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C24T variant allele in MRP2 under cyclosporine treatment
Trial: 22713999
Drug: Acetaminophen plus
RxNorm normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen plus ibuprofen (AcIBU)
Trial: 18308218
Drug: Acetaminophen plus
RxNorm normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen plus codeine plus caffeine (Tylenol No. 3)
Trial: 10875715
Drug: Morphine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.15 mg x kg(‐1) (R/M15 group)
Trial: 10875715
Drug: Morphine 0.20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.20 mg x kg(‐1) (R/M20 group)
Trial: 23062389
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (BDP) nasal aerosol 320 μg/day
Trial: 23062389
Drug: Placebo/prednisone (prednisone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo/prednisone (prednisone 10 mg/day for the last 7 days)
Trial: 16823241
Drug: Continuous IV
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous IV administration of NIC
Trial: 16823241
Drug: Continuous IV
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous IV and oral administration of NIC
Trial: 16823241
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment with NIC (Control group)
Trial: 15678619
Drug: Avasimibe 50
RxNorm normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avasimibe 50 mg
Trial: 15678619
Drug: Avasimibe 250
RxNorm normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avasimibe 250 mg
Trial: 15678619
Drug: Avasimibe 750
RxNorm normalized name: Avasimibe
DrugBank: Avasimibe (DB06442)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avasimibe 750 mg
Trial: 8978584
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg plus dexamethasone 20 mg (8 mg group)
Trial: 8978584
Drug: Ondansetron 24
RxNorm normalized name: ondansetron 24 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 24 mg plus dexamethasone 20 mg (24 mg group)
Trial: 23199009
Drug: 0.5‐1.0 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5‐1.0 μg calcitriol and 1,200 IU (30 μg) cholecalciferol
Trial: 20572581
Drug: Radiotherapy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy combined with daily low-dose carboplatin (arm II)
Trial: 20572581
Drug: Radiotherapy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy combined with daily low-dose carboplatin (arm II) in stage IV disease
Trial: 16532872
Drug: Shin Saver
RxNorm normalized name: acetaminophen / diphenhydramine hydrochloride Oral Tablet [Tylenol Severe Allergy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shin Saver orthosis treatment group
Trial: 3536293
Drug: Trientine 300
RxNorm normalized name: trientine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trientine 300 mg daily
Trial: 29447772
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 75-160 mg daily
Trial: 25941174
Drug: Daily ozone
RxNorm normalized name: ozone
DrugBank: Ozone (DB12510)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ozone levels on the day before a PCV
Trial: 25941174
Drug: Daily PM2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily PM2.5 levels on the day before a PCV (December to March)
Trial: 15504288
Drug: Sequence administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequence administration of lamivudine and interferon alpha 1b
Trial: 15504288
Drug: No anti-virus
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anti-virus therapy (control group)
Trial: 9307197
Drug: Preradiation chemotherapy
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preradiation chemotherapy consisting of methotrexate 120 mg/m2, cisplatin 100 mg/m2, 5-fluorouracil 1000 mg/m2 for five days, leucovorin 25 mg/m2 every six hours for 6 doses, followed by radiation therapy and adjuvant IFN-beta (10^5 U/kg) 3 times a week for 6 months.
Trial: 9307197
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with a cumulative dose of 59.4 Gy to primary sites and 45 Gy to the neck area.
Trial: 8354807
Drug: Central administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Central administration of adenosine (3 mg)
Trial: 8354807
Drug: Central administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Central administration of adenosine (6 mg)
Trial: 8354807
Drug: Central administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Central administration of adenosine (9 mg)
Trial: 8354807
Drug: Peripheral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peripheral administration of adenosine (3 mg)
Trial: 8354807
Drug: Peripheral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peripheral administration of adenosine (6 mg)
Trial: 8354807
Drug: Peripheral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peripheral administration of adenosine (9 mg)
Trial: 8354807
Drug: Peripheral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peripheral administration of adenosine (12 mg)
Trial: 24101860
Drug: Aescin 10%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aescin 10% cream applied immediately after the procedure, in the evening, and the morning after
Trial: 21843889
Drug: 21 active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 21 active pills + 7 placebo pills (21/7 COC)
Trial: 21843889
Drug: 24 active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 active pills + 4 placebo pills (24/4 COC)
Trial: 17885297
Drug: High maternal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High maternal CRP concentration (> 10 mg/l)
Trial: 15153210
Drug: Ketamine 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 6 mg.kg(‐1) per oral
Trial: 9564606
Drug: Selegiline (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (10, 30, or 60 mg/day for three or more weeks)
Trial: 9564606
Drug: Pargyline (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pargyline (90 mg/day for three or more weeks)
Trial: 9564606
Drug: Clorgyline (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorgyline (30 mg/day for three or more weeks)
Trial: 9564606
Drug: Selegiline (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline (higher doses than 10 mg/day)
Trial: 9564606
Drug: Selegiline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline and Pargyline (highest doses)
Trial: 31362061
Drug: OLE treatment
RxNorm normalized name: limonen-10-ol, (+)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLE treatment
Trial: 23980349
Drug: Xiaozhi Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaozhi Capsule (XZC)
Trial: 23980349
Drug: Xuezhikang Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuezhikang Capsule (XZKC)
Trial: 17853008
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg/daily for 4 weeks
Trial: 17853008
Drug: Diclofenac 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac 100 mg on demand for 4 weeks plus levofloxacin 250 mg daily for the first week
Trial: 16597040
Drug: Naftopidil (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naftopidil (25 mg once a day for 4 weeks)
Trial: 11181464
Drug: Ramipril 10
RxNorm normalized name: ramipril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril 10 mg/d
Trial: 11001109
Drug: 7-valent pneumococcal
RxNorm normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-valent pneumococcal conjugate vaccine (7VPnC) administered as a separate injection